Allosteric Modulators for β2AR Signaling Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current asthma treatments using β2-adrenergic receptor agonists face challenges due to long-term side effects and a lack of integration of dynamic signaling modalities in drug discovery, leading to reduced therapeutic response and increased risk of adverse effects.
Innovation Solution
Development of β2-adrenergic receptor-specific allosteric modulators, such as compounds of formulas (1), (2), and (3), which selectively promote β2AR interaction with Gs, thereby preventing or treating airway diseases like asthma and COPD by modulating signaling pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional β2AR agonists are used for long-term asthma treatment, then airway relaxation is achieved, but therapeutic response is lost and adverse effects increase
Solution Approach 1:
The patent segments the β2AR into two distinct binding sites: the orthosteric site (where endogenous ligands bind) and the allosteric site (where the novel compounds bind). By targeting the allosteric site separately, the invention achieves airway relaxation without activating the orthosteric site, thereby avoiding the desensitization and adverse effects associated with conventional agonists.
Solution Approach 2:
The allosteric modulator acts as an intermediary that enhances or modulates the receptor's response to endogenous ligands without directly activating the receptor through the orthosteric site. This intermediary approach allows for sustained therapeutic effect by preserving the receptor's natural regulation mechanisms while still achieving the desired airway relaxation.
2Adaptability or versatility
If conventional GPCR drug discovery strategies are used, then orthosteric site binding is investigated, but dynamic signaling modalities are not integrated leading to side effects
Solution Approach 1:
The patent adds a new dimension to GPCR drug discovery by moving from single-site (orthosteric) targeting to dual-site (orthosteric + allosteric) targeting. This dimensional expansion allows for integration of multiple signaling modalities simultaneously, enabling more nuanced control over receptor activation and reducing off-target effects.
Solution Approach 2:
The invention changes the binding parameter from orthosteric site affinity to allosteric site modulation. By altering which site on the receptor is targeted, the drug achieves different signaling outcomes with improved safety profiles. The allosteric modulators can fine-tune receptor activity without the all-or-nothing activation characteristic of orthosteric agonists.
Data Source
AI summary
The β2-adrenergic receptor (β2AR) is a primary target in the treatment of airway diseases such as asthma and chronic obstructive pulmonary disease (COPD). Since β-agonist treatment of airway disease can have severe side effects, compounds that attenuate the side effects of β-agonists have been identified via their ability to inhibit β2AR interaction with β-arrestins. These compounds are specific for the β2AR and effectively protect against the desensitization observed with β-agonist treatment in model cells and airway tissue. The present disclosure provides compounds and methods for treating airway disease, such as but not limited to COPD and/or asthma.